tbuckley/cabot-search huggingface dataset:
Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial.
Authors: Jun J. Mao, Kevin Liou, Katherine Panageas, Raymond E Baser, Sally A. D. Romero, Qing Susan Li, Han Xiao, Ting Bao, Philip W. Kantoff
Journal: Journal of Clinical Oncology (2020)

12004 Background: The national opioid crisis has created new challenges in oncology pain management and highlighted an urgent need for non-pharmacological treatments. We evaluated the comparative effectiveness of electro-acupuncture (EA) and auricular acupuncture (AA) versus usual care (UC) for chronic musculoskeletal pain in cancer survivors. Methods: We conducted a randomized controlled trial of cancer survivors experiencing moderate-severe musculoskeletal pain for at least 3 months. EA used a semi-individualized protocol involving electrical stimulation of needles placed in the body. AA used the standardized Battlefield Acupuncture protocol involving up to 10 needles placed in the ears. EA and AA groups received 10 weekly treatments, whereas participants in the UC group received standard care prescribed by their providers. The primary endpoint was average pain severity change measured by the Brief Pain Inventory at week 12 compared to baseline. Functional interference and quality of life were secondary outcomes. We analyzed longitudinal mixed-effects models based on intent-to-treat principles. Results: Among 360 participants, mean age (SD) was 62.1 (12.7) years, 251 (69.7%) were women, and 88 (24.4%) were non-white. Compared from baseline to week 12, EA significantly reduced pain severity by 1.9 points (95% Confidence Interval 1.5-2.3, p &lt; 0.001), and AA significantly reduced pain severity by 1.6 points (1.1-2.0, p &lt; 0.001). AA was non-inferior to EA at reducing pain severity (p = 0.04). Both EA and AA also significantly improved functional interference (both p &lt; 0.001), physical health (both p &lt; 0.001), and mental health (p = 0.003, p &lt; 0.001) compared to UC. Adverse events (AEs) were mild in both groups; however, 16 (11.2%) in AA stopped treatment due to AEs (mostly ear discomfort) as compared to 1 in EA (0.7%), p = 0.001. Conclusions: Among cancer survivors with chronic musculoskeletal pain, both EA and AA effectively reduced pain and improved quality of life. AA was non-inferior to EA at reducing pain but associated with higher discontinuation rates. These results will guide implementation of acupuncture in oncology care to address the unmet pain management needs of cancer survivors in the era of the opioid epidemic. Clinical trial information: NCT02979574 .
类风湿关节炎的中医治疗
Authors: 冯兴华
Journal: BMJ (2005)

类风湿关节炎(rheumatoid arthritis,RA)属中医学痹证的范畴,现在把痹证 也称为痹病.痹有闭的意思,是指气血运行不畅.古代医籍中有关风湿、历节、痛风、鹤膝风等病的描述也与本病相似,同属于痹证的范畴.痹病是人体的正气不足,感受外界的风寒湿热等邪气后,经络气血运行不畅而引起的关节肌肉疼痛、肿胀、重着、麻木、酸楚、屈伸不利,甚则关节僵直、畸形的一种疾病。
过敏原皮肤试验引起全身反应三例
Authors: 刘瑞玲, 石富兰, 马瑞琴
Journal: BMJ (2005)

例1 男,27岁,因哮喘、可疑牛奶过敏于1993年4月来诊.行牛奶皮试 3 min后出现胸闷、憋气、喘鸣、端坐呼吸、三凹征,血压140/90 mm Hg(1 mm Hg= 0.133 kPa),脉搏90次/min.立即吸入沙丁胺醇气雾剂,肌肉注射地塞米松10 mg,苯海拉明40 mg.约15 min后缓解。
To scan or not to scan: An evaluation of preoperative MRI use in primary breast cancer assessments.
Authors: Tesia McKenzie, Davina Matinho, Olivia Scott, Arbaz Khan, Mila Lachica, Arthur A. Topilow, Denise Johnson Miller, Michelle Secic
Journal: Journal of Clinical Oncology (2020)

e14146 Background: Breast cancer (BC) is the most common invasive cancer in adult females.The role of preoperative MRI in assessing the extent of primary breast cancer remains controversial. This study’s objective is to determine if MRIs performed after the diagnosis of invasive/non-invasive-breast cancer will identify additional breast cancers. We hypothesize that preoperative MRIs will result in the discovery of additional significant lesions, leading to changes in surgical treatment. Methods: A retrospective study of 389 BC patient charts were reviewed, dated from January 2000- July 2019. Files were collected from an office in the Breast Cancer Surgery Department. Information on each patient’s imaging studies, treatment, demographics, surgery, and pathology were collected and stored in anonline cloud system. Summary statistics, including proportions, percentages, and difference of proportion hypothesis tests were utilized to interpret the data. All statistical tests were conducted at a 95% confidence interval. Results: We reviewed the charts of 335 patients that met eligibility criteria. In 221 newly diagnosed cancers, a preoperative MRI was taken before treatment. 127 cancers (57.5%)showed additional finding.In BC patients with additional preoperative MRI findings, we observed 61.4%true positive and 38.6%false positive results. These values are comparable to prior studies.We determined that the treatment plan was altered in 17.6%of all patients who received an MRI and in 30.7%of patients with a true positive MRI finding, which is also consistent with previous literature.A majority of the treatment changes were from Lumpectomy to Mastectomy. Conclusions: Literature on MRI use in BC diagnosis exists; our study differs by focusing on newly diagnosed breast cancers.We discovered 35.3% of preoperative MRIs identified a true additional finding in known breast cancer. In addition, our true positive rate (61.4%) and false positive rate (22.2%) of MRI findings is comparable to those of previous studies. Plans were changed in 30.7% of additional findings supporting the idea that preoperative MRI studies are useful when organizing surgical treatment. Further studies to demonstrate the impact on local recurrence rates and overall survival, may clarify the true role of pre-operative MRI in these cases.
冠心病患者的合理用药
Authors: 李俭春
Journal: BMJ (2007)

影响冠心病预后的主要是动脉壁粥样硬化斑块的性质.经皮冠状动脉介入术(PCI)已成为冠心病尤其是急性冠状动脉综合征(ACS)的重要治疗手段,但它并没有削弱或取代药物治疗.相反,PCI术后更应强化抗栓、降脂等药物治疗,因为PCI并没有、也不能抑制动脉粥样硬化的发生发展,术后再狭窄的防治在很大程度上有赖于药物。
The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
Authors: Sant P. Chawla, Victoria S. Chua, Katherine Kim, Paul Stendahl Dy, Micaela Kristina Paz, Nicole Angel, Kelly Wang, Ania Moradkhani, Doris Quon, Steven Wong, Omid Jafari, Erlinda Maria Gordon
Journal: Journal of Clinical Oncology (2020)

TPS11572 Background: Talimogene laherparepvec (TVEC), an oncolytic HSV expressing huGMCSF, may be synergistic with trabectedin (T) and nivolumab (N) in treating advanced sarcoma. Objectives: (1) To evaluate the best overall response by RECIST v1.1, progression-free survival rate (PFS), and overall survival rate, (2) To determine the incidence of conversion of an unresectable tumor to a resectable one, and (3) To evaluate the incidence of adverse events related to the drug combination. Methods: This is an open label phase 2 study. A total of 40 patients will receive T (1.2 mg/m2 CIV over 24 hours q3 weeks), N (240 mg IV over 30 min q 2 weeks) and TVEC (intratumorally q 2 weeks according to tumor size). Eligible patients are those with histopathologically confirmed diagnosis of locally advanced, unresectable or metastatic sarcoma including desmoid tumor and chordoma, previously untreated or treated, with measurable disease by RECIST v1.1, and at least, one accessible tumor for intratumoral injection of TVEC. Currently, 31 of the 40 patients have been enrolled. Statistical Considerations: Continuous variables will be summarized by the sample size (n), mean, standard deviation, first and third quartiles, minimum and maximum. Categorical variables will be summarized by the n and percent in each category. Point estimates for efficacy endpoint incidences will be accompanied by a 2-sided 95% exact binomial CI. Time to event endpoints will be summarized descriptively using the KM method. Safety (incidence and severity of adverse events and significant laboratory abnormalities) will be performed on all patients (ITT population). Patient incidence of all treatment emergent AEs will be tabulated by system organ class and preferred term. Clinical trial information: 03886311 .
e-Health preparedness assessment in the context of an influenza pandemic: a qualitative study in China
Authors: 李俊华, Seale Holly, Ray Pradeep, 王全意, 杨鹏, 李爽, 张奕, MacIntyre C Raina
Journal: BMJ (2013)

目的
在流感大流行的环境下，对北京地区医院应用电子医疗系统的准备情况开展评估。


设计
采用定性研究的方法。研究分为两个阶段：(1)应用小组访谈，对相关人士就北京地区电子信息技术在疾病监测方面应用的情况进行访谈，为第二阶段的研究提供必要的背景资料。(2)应用个人访谈，收集入选医院有关应用电子医疗系统的准备情况的相关资料。


研究地点
第一阶段研究在北京市疾病预防控制中心进行。第二阶段研究在北京市选定的一家二级医院开展。


研究对象
在第一阶段，将应对北京2009年甲型H1N1流感大流行的12名核心人物分为3个小组，进行小组访谈。研究对象为来自北京市疾病预防控制中心(简称：疾控中心)、两个区县疾控中心及一个三级医院的公共卫生医师和临床医生。第二阶段，对23名研究对象进行了个人访谈。其中包括内科医生、一位信息技术管理员和一位行政管理人员。


第一阶段及第二阶段的实施方法
在大流行的环境下，研究从5个方面对医院应用电子医疗系统的准备情况进行了评估：(1)激励改革的动力；(2)医务人员对电子医疗系统的接触情况；(3)技术储备；(4)支持临床电子信息技术革新组织的非技术能力；(5)组织机构中，与应用电子医疗系统和应对流感大流行相关的社会问题。


结果
文中报告了案例研究结果中的一部分，从中反映了医院在准备方面的3个主要问题。分别为：病人病历的共享程度差，处方错误，没有有效的软件系统帮助医生回答病人的问题，医师对电子医疗系统的可信性存有疑虑，应用电子医疗系统需要较大的资金投入以及对于投资后回报的不确定性、医生对于目前使用的软件表示不满意。


结论
在电子医疗系统投入应用之前，有必要先制定计划以保证医务人员能顺利的接受电子医疗系统。在这个计划中，对组织机构准备状况的评估是重要一步。案例研究的结果表明，对于应用电子医疗档案，医院的准备尚有不足之处。因此，我们建议解决上述问题，以促进电子医疗系统的应用。
Abstract 247: Development and Evaluation of Standardized Communication for In-Hospital Resuscitation
Authors: Kasper G Lauridsen, Ichiro Watanabe, Akira Nishisaki, Robert A Berg, Dana E Niles, Elizabeth A HUNT, Jordan M Duval-arnould, Grace L Good, Adam Cheng, Bo Løfgren, Vinay M Nadkarni
Journal: Circulation (2019)

Background: Recommendations for “standardized” communication during cardiopulmonary resuscitation (CPR) events to reduce interruptions in chest compressions (CCs) are lacking. We aimed to achieve consensus on standardized communication during in-hospital CPR, evaluate feasibility and potential to decrease CC pauses, mental task load, and frustration. Methods: Modified Delphi consensus surveys of International Liaison Committee on Resuscitation taskforce members to identify preferred communication for in-hospital cardiac arrest teams. Consensus was reached after-survey teleconference resolution by a team of interdisciplinary experts in communication and CPR. Feasibility was tested in 8 simulated CPR scenarios with physician team leaders randomized (1:1) to ‘standardized’ communication vs. “usual best practice”, closed loop communication. Team leaders watched a 3-min video and received a 10-min training on the assigned intervention before the CPR scenario. NASA task load index questionnaires were used to assess mental task load and frustration (0=lowest to 100=highest). Results: Modified Delphi consensus on standardized communication included: 1) preparing the team 15-30 seconds before interrupting CCs, 2) countdown for interruption synchronized with 5 CCs, 3) action words for stopping and resuming CCs, 4) action words for intubation and defibrillation. Among 8 CPR teams (4 standardized, 4 usual communication), median (Q1; Q3) CC interruption duration for rhythm check was significantly shorter, 5.3 (4.8; 6.8) vs. 9.4 (6.4; 13.0) sec for standardized vs. closed loop communication [p=0.02]. Median (Q1; Q3) scores of mental task load were 63 (33; 70) vs 85 (70; 96), [p=0.10] and frustration 10 (5; 34) vs 40 (26; 50) [p=0.11] for standardized vs. closed loop communication. Trained team leaders adhered to standardized phrases 77% of the time. Conclusion: Expert consensus for standardized communication during in-hospital CPR was achieved. Pilot simulation implementation of standardized communication demonstrated feasibility of team leader adherence, significantly decreased duration of CC interruption during rhythm checks, and a tendency to reduce team leader task load and frustration.
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.
Authors: Betina Yanez, Robert James Gray, Joseph A. Sparano, Ruth Carlos, Gelareh Sadigh, Sofia F. Garcia, Ilana F Gareen, Timothy Joseph Whelan, George W. Sledge, David Cella, Lynne I. Wagner
Journal: Journal of Clinical Oncology (2020)

7004 Background: The TAILORx study demonstrated women with an intermediate Oncotype DX score receive the same benefit with endocrine therapy (ET) compared to chemoendocrine therapy (CET). However, early discontinuation of adjuvant ET is problematic among breast cancer survivors, with previous studies suggesting that up to 50% of women do not adhere to the full 5 years of recommended ET treatment. The aim of this study was to identify patient-level risk factors associated with early discontinuation of ET in the TAILORx study. Methods: TAILORx was coordinated by the ECOG-ACRIN Cancer Research Group. Participants were a subgroup of 954 women who completed additional measures on health-related quality of life (HRQoL) including endocrine symptoms (ES) physical well-being (PWB) and social well-being (SWB) prior to initiating ET, which categorized into three groups by tertile for analysis. All participants were diagnosed with hormone-receptor–positive, human epidermal growth factor receptor 2–negative, axillary node–negative breast cancer who started ET within a year of study entry. Early discontinuation of ET, defined as discontinuation less than 4 years from initiation for reasons other than death or recurrence, was assessed by clinician report. Rate of discontinuation was calculated using Kaplan-Meier estimates, and Cox-proportional hazards joint models were used to analyze the association between rates of adherence to ET with patient-level factors. Results: In a joint model, receipt of CET therapy (vs receipt of ET only; HR = .59, 95% CI .38-.94, p = .02) and age above 40 (versus age &lt; = 40; HR = .30, 95% CI .14-.66, p = .003) were associated with a lower probability of early discontinuation of ET. Adjusted for these factors, a history of depression compared to no history of depression (HR 1.82, 95% CI 1.19-2.77, p = 0.005), worse ES compared to better ES (HR 1.70, 95% CI 1.06-2.74, p = 0.03), worse PWB compared to better PWB (HR 2.12, 95% CI 1.30-3.45,p = 0.003), and worse SWB compared to better SWB (HR 1.94, 95% CI 1.20-3.13, p = 0.007) were individually and significantly associated with a higher probability of early discontinuation of ET, although none reached statistical significance when all were included in a joint model. Conclusions: Younger women are at risk for early discontinuation and modifiable characteristics such as HRQoL and history of depression are potential risk factors for early discontinuation of ET. These results support systematic screening for HRQoL and depressive symptoms to identify women at risk for discontinuation of ET. Clinical trial information: NCT00310180 .
Abstract 16726: N-Cadherin Overexpression Improves the Reparative Potency of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Infarcted Mouse Hearts
Authors: Xi Lou, Meng Zhao, Chengming Fan, Vladimir Fast, Ling Gao, Yawen Tang, Wuqiang Zhu, Jianyi Zhang
Journal: Circulation (2018)

Background: Stem-cell-based therapy is a promising approach for the treatment of myocardial infarction (MI); however, the effectiveness of the treatment is believed to be limited by the poor survival and functional integration of transplanted cells. Within the heart, the adhesion between cardiomyocytes (CMs) is mediated by N-cadherin (CDH2), and CDH2 expression is well correlated with the efficacy of mesenchymal stem cells for myocardial repair. Thus, we determined whether the electrical connectivity, engraftment, and reparative potency of human induced-pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs) can be improved via CDH2 overexpression. Materials and methods: Conduction velocities were measured in cultured CDH2-overexpressing hiPSC-CMs (CDH2-CMs) and wild-type hiPSC-CMs (WT-CMs) via optical mapping. MI was induced in SCID mice via coronary artery ligation; then, the mice were treated with CDH2-CMs or WT-CMs (310 5 cells/mouse) (i.e., the MI+WT-CM and MI+WT-CM groups, respectively), or with neither experimental treatment (the MI group). The cells were injected directly into the infarcted region of the heart, cardiac function and infarct size were evaluated via post mortem examination, and the engraftment rate was evaluated histologically. Results: In-vitro conduction velocities were significantly greater (p&lt;0.05) in CDH2-overexpressing hiPSC-CMs than in wild-type hiPSC-CMs, while in-vivo measurements of cardiac function (left-ventricular ejection fraction and fractional shortening), infarct size, and the hiPSC-CM engraftment/survival rate at week 4 after MI were significantly better in the MI+CDH2-CM group than in MI+WT-CM animals and in both cell-treatment groups than in MI animals . Conclusion: N-cadherin overexpression improves the electrical connectivity of cultured hiPSC-CMs, as well as the engraftment/survival and reparative potency of transplanted hiPSC-CMs in infarcted mouse hearts. Key words: N-cadherin, Myocardial Infarction, human induced pluripotent stem cells.
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
Authors: Natasha B. Leighl, Mary Weber Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence Howard Schwartz, James Lloyd Wade, William Johnson Irvin, Sreekanth Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Tom Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Vassiliki Papadimitrakopoulou, Karen Kelly
Journal: Journal of Clinical Oncology (2020)

9623 Background: The Lung Cancer Master Protocol (Lung-MAP) is designed to evaluate novel targeted therapies in patients with advanced squamous lung carcinoma. In the S1400F sub-study (non-match), we tested whether combined CTLA-4 and PD-1 inhibition with durvalumab plus tremelimumab (D+T) could overcome primary or acquired resistance to anti-PD-(L)1 therapy. Response, progression-free (PFS) and overall survival, and safety in the acquired resistance cohort are reported herein. Methods: Patients with previously treated squamous lung carcinoma, performance status (PS) 0-1, and adequate organ function that developed disease progression after ≥24 weeks of anti-PD-(L)1 monotherapy were eligible. Prior severe immune-related toxicities, intervening systemic therapy and combination chemo-immunotherapy were not permitted. Patients received D1500 mg + T75 mg IV q28 days for 4 cycles then D maintenance until disease progression. The primary endpoint was best objective response (RECIST 1.1). Interim analysis for futility was planned after 20 patients evaluable for response were enrolled. If no responses were observed, the cohort would stop enrolment. Results: 30 eligible patients were accrued to the acquired resistance cohort. Median age was 68 years, 60% of patients were male, 33% PS 0 and had received a median of 2 prior lines of therapy (maximum 4). Best response to prior anti-PD-(L)1 therapy was CR/PR/SD in 3/7/20 patients, with a median duration of anti-PD-(L)1 therapy of 8.6 months (5.2-30.4). No objective responses were seen with D+T; 47% had SD as best response. Median PFS was 2.0 months (95% CI 1.6-2.9) and survival 7.5 months (95% CI 5.3-8.7). Among the 14 patients with SD as best response, the median PFS calculated from first disease assessment is 2.8 months (95% CI: 1.4-3.9). Grade≥3 adverse events at least possibly related to protocol therapy were seen in 10/30 patients. These include 1 treatment-related death due to pneumonitis and 1 death not otherwise specified. Other adverse events include grade 3 confusion (1), dehydration (2), diarrhea (3), encephalopathy (1), weakness (1), hyperglycemia (1), hypoxia (1), lymphopenia (1), nausea, (1), neutropenia (1), thrombocytopenia (1), rash (1), vomiting (1), grade 4 dyspnea (1), leucopenia (1) and lymphopenia (1). Conclusions: D+T did not demonstrate activity in patients with acquired resistance to PD-1 checkpoint inhibitors and pretreated advanced squamous lung carcinoma. Clinical trial information: NCT03373760 .
An Array of Studies Addressing Cognition and Cognitively Defined Neuropsychiatric Conditions: Many More Connections Than You Might Think
Authors: Philip D. Harvey
Journal: American Journal of Psychiatry (2020)

Six articles in the June 2020 issue of the American Journal of Psychiatry address the overall construct of cognition. These articles have a broad connection to cognition, which is itself a broad concept. From the experimental psychology perspective, cognition is the set of processes associated with attending, learning, knowing, and remembering. From the clinical perspective, a number of neuropsychiatric conditions are defined by the presence of cognitive impairment, with onset ranging from childhood, such as attention deficit hyperactivity disorder and intellectual disability, to later life, such as dementia. Other conditions have notable cognitive impairments even if specific cognitive impairments are not an explicit part of their formal diagnostic criteria, including autism spectrum disorder and schizophrenia. Thus, the array of articles in this issue are related to each other and also may make important points about the role of cognition in everyday functioning and the connections between cognitive impairments in neuropsychiatric conditions and in the human population in general. Further, these articles address the neurobiological substrates that have an impact on cognition, with important implications in other domains, such as genomics. Finally, through sophisticated research methods, they clarify the results of previous studies that were affected by a variety of methodological challenges.
Complications and related risk factors in Uygur patients with type 2 diabetes mellitus
Authors: Guoli Du, Yinxia Su, Jun Zhu, Sheng Jiang, Jing Xu, Yimingjiang Ayiguli, Fugang Chen, Hua Yao
Journal: BMJ (2019)

Objective
To investigate the prevalence of complication and related risk factors in Uygur patients with type 2 diabetes mellitus (T2DM).


Methods
Total 1 507 Uygur patients aged above 20 with T2DM were recruited in the First Affiliated Hospital of Xinjiang Medical University from January 2010 to October 2015. Clinical characteristics, biochemical parameters and related complications were analyzed in different age groups of patients. Multivariate logistic regression was performed to determine associated factors for diabetic complications.


Results
Among 1 507 cases, there were 61.3% male patients (n=924), 37.4% (n=564) with diabetes duration ≥5 years, 12.5% (n=189) with HbA1c>10%, 31.5% (n=475) with hypertension, 28.8% (n=434) with smoking history and 37.4% (n=564) patients without antidiabetic drug treatment. The average body mass index (BMI) of patients was (27.4±5.2) kg/m2 with a obesity rate of 43.0% (648/1 507), and 65.0% (980/1 507) had physical exercise 10% (OR=2.74, 95%CI: 1.40-5.34), obesity (OR=1.54, 95%CI: 1.07-2.21), systolic pressure≥140 mmHg (1 mmHg=0.133 kPa) (OR=1.42, 95%CI: 1.01-1.99), diastolic pressure≥90 mmHg (OR=0.37, 95%CI: 0.21-0.67), smoking (OR=1.53, 95%CI: 1.09-2.15) and physical activity<150 min/week (OR=1.42, 95%CI: 1.07-1.89) were the risk factors of diabetic complications.


Conclusion
Uygur patients with type 2 diabetes in Xinjiang show a relatively high prevalence of complications.Poor glycemic control,obesity,hypertension,smoking and physical inactivity may contribute to development of complications, while well-controlled blood glucose and hypertension and quitting smoking and increasing physical activity may reduce diabetic complications.


Key words: 
Diabetes mellitus, type2; Diabetes complications; Age factors; Disease duration; Blood glucose
The regulation mechanism of hypoxia-inducible factor-1 and its relationship with liver disease
Authors: 何玉兰, 孟庆华
Journal: BMJ (2010)

缺氧诱导因子-1(hypoxia-inducible factor-1,HIF-1)是缺氧条件下广泛存在于哺乳动物和人体内的一种转录因子.它通过诱导基因表达而促进细胞和整个机体从常氧(20%O2)到缺氧(1%O2)状态的适应和存活[1],进而参与多种疾病过程.肝脏是机体的主要代谢器官,肝癌、酒精性肝病、肝硬化等都会导致肝脏局部或广泛缺氧.近年来,很多学者研究了HIF-1的表达及与肝脏疾病的关系,现对此做一综述。